WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ABUS, an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be participating in the following investor conferences in October 2019:
Cantor Fitzgerald Global Healthcare Conference – New York
Friday, October 4, 2019, 1:10 PM ET
Presentation: William H. Collier
Chardan Genetic Medicines Conference – New York
Monday, October 7, 2019, 8:00 AM ET
Fireside Chat: William H. Collier and Dr. Gaston Picchio
Live webcasts of the presentations can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com. A replay of the webcasts will be available for 90 days following the live presentations.
About Arbutus
Arbutus Biopharma Corporation is a publicly-traded ABUS biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.
Contact Information
Investors
William H. Collier
President and CEO
Phone: 604-419-3200
Email: ir@arbutusbio.com
Media
Pam Murphy
Investor Relations Consultant
Phone: 604-419-3200
Email: ir@arbutusbio.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
